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1. Introduction
The link between immune responses and cancer is evident from findings such as, a com‐
promised immune system resulting in an increased tumour incidence [1] and cancer pa‐
tient  sera evidencing recognition of  autologous cancer antigens [2].  The identification of
tumour associated antigens (TAAs) plays a central role in our understanding of how can‐
cer cells can inhibit the immune system and how we can overcome this tumour immune
suppression  to  break  tolerance  and  achieve  cancer  destruction  [3].  Antibodies  reacting
with  TAAs  on  the  surface  of  cancer  cells  provoke  an  extremely  effective  immune  re‐
sponse  [4]  which  can  be  exquisitely  specific  to  the  tumour  cells  present  in  the  body.
However not many surface proteins are present on tumour cells and limited otherwise in
expression to healthy non-essential tissues.
TAAs are most often proteins which have acquired mutations or have elevated expression
levels which are expressed at the sub-cellular level. The ideal immunotherapy targets should
also play a role in tumour progression [5]. For example p53 [6] is one of the most desirable
targets for immunotherapy – targeting p53 can kill both the evolving tumour cell population
and any cancer “stem” cell which harbours this as an early tumourigenesis aberration and
supports further tumour growth. In addition, a number of tumour antigens have been shown
to be useful biomarkers for cancer diagnosis [7] and survival [8].
In this chapter, we will examine how tumour antigens are identified and characterised to
demonstrate their potential as immunotherapy targets and examine their role as biomarkers
for treatment response and patient survival, and targets for personalised therapies.
© 2013 Khan et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Which tumour antigens?
Many of the tumour antigens identified by serological identification of antigens by recombi‐
nant expression cloning (SEREX) can be classified into one or more categories which are:
cancer-testis, mutational, differentiation, amplified/overexpressed, splice variant and viral
antigens [9]. Cancer-testis (CT) antigens [10] have been found to be highly expressed in tu‐
mours but not in normal tissues with the exception of immunologically protected sites
(those tissues which lack major histocompatibility complex (MHC) class I and therefore do
not present self-antigens). CT antigens make attractive targets as due to their limited expres‐
sion, they should therefore induce specific anti-tumour immune responses and less toxicity
to healthy tissue [11]. However some debate remains as to the definition of a CT antigen [12]
with some suggestion of differential levels of expression and others suggesting no expres‐
sion in normal tissues expect those in immunologically protected sites (such as ovary, pla‐
centa and testis). TAAs that are frequently found in tumours and provide excellent targets
for immunotherapy include Wilms tumour 1 [13] and PRAME [14].
3. Identification of tumour antigens
Strategies are required to help identify potential targets which can be used for cancer immuno‐
therapy. Some of the most commonly used and successful techniques are described as follows:-
3.1. Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) and real-time PCR (RQ-
PCR)
Reverse-transcription-polymerase chain reaction (RT-PCR) and real-time PCR (RQ-PCR) has
been used to examine known TAA expression in a range of solid and haematological malig‐
nancies [15-19]. Although this has provided important expression information and a good
starting point to identify potential antigenic targets in a range of cancers, these studies are
entirely limited to tumour antigens which had already been discovered.
3.2. Representational difference analysis
Representational difference analysis was developed by Thierry Boon’s group and used to
discover a number of CT antigens [20, 21] including the MAGE family of antigens, typically
from melanoma with one exception, RAGE, from renal cancer. Briefly, total RNA was ex‐
tracted from normal tissue (driver) and a tumour sample (tester) and used to construct dou‐
ble-stranded cDNA. Both cDNA samples were digested with the restriction enzymes DpnII
and ligated to adapters which contained primer binding sites. The fragments were amplified
by PCR, the adapters removed and new adapters for unrelated primers ligated to the tester.
The tester and driver were then mixed and hybridized leading to three combinations of
product: driver-driver (no amplification), tester-driver (linear amplification) and tester-test‐
er (exponential amplification). A further two hybridization and amplification steps generate
greater variation in the products which are subsequently cloned and sequenced.
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3.3. Serological identification of antigens by recombinant expression cloning (SEREX)
Serological identification of antigens by recombinant expression cloning (SEREX) provided a
much needed boost to the area of antigen identification at a time when few cancer antigen
identification options existed [2]. SEREX was not limited to immunogenic cancers such as
melanoma and has now been used to identify more than 2,000 antigens [22-23] in a large
range of different solid [24-26] and haematological malignancies [27-30]. cDNA libraries are
created from tumour samples, cell lines or healthy normal donor cells (such as testes). RNA
from these cells were reverse transcribed and inserted as cDNA into phage vectors and ex‐
pressed as recombinant proteins on the capsid surface of phage which survived on permis‐
sive E.coli. Expressed proteins were transferred to nitrocellulose membranes and following
the removal of excess E.coli waste, phage plaques were immunoscreened using pre-cleared
patient sera. Any positive plaques were isolated, eluted and used for secondary confirmato‐
ry screening, prior to cDNA sequencing of phagemid inserts [31].
3.4. Serological proteome analysis (SERPA)
Serological proteome analysis (SERPA) was first described by Klade et al in 2001 [32]. Proteins
were extracted from primary tumours or cell lines, separated concurrently on two 2D gels and
transferred to nitrocellulose membranes. A third gel is stained with Coomassie Blue as a prepa‐
rative gel. The membranes are incubated with cancer patient’s sera and normal control. The two
gels are directly compared and any bright spots on the cancer sera membrane were cut from the
preparative gel and indentified using mass spectrometry [33, 34].
3.5. CDNA microarrays
The differential expression of tumour antigens and/or protein biomarkers between cell and dis‐
ease subtypes have been directly compared on cDNA microarrays and has allowed our im‐
proved  understanding  of  lymphomas  [35]  and  aided  our  development  of  personalised
therapies [36]. Microarray technology is able to distinguish between different subtypes of a par‐
ticular cancer as well as identify the expression of novel antigens [37]. Minimal residual disease
is a very important tool in the detection of impending relapse in patients who have had some
form of treatment. Markers for minimal residual disease in acute lymphocytic leukaemia were
identified by gene profiling [38]. cDNA microarray has been used to identify the frequency of
elevated tumour antigen expression in acute myeloid leukaemia [28] and also associations be‐
tween specific cytogenetic abnormalities and relative levels of tumour antigen expression [39].
Micorarray has also been used to elucidate the possible function of tumour antigens such as
Synovial Sarcoma X breakpoint 2 Interacting Protein (SSX2IP) in the subversion of cells har‐
bouring cytogenetic abnormalities (t(8;21) associated with mitotic spindle failure and the asso‐
ciation between the elevated expression of some tumour antigens (SSX2IP, RHAMM and
SURVIVIN) at disease presentation and patient survival [8] in acute myeloid leukaemia.
3.6. Mass Spectroscopy (MS)
Mass Spectroscopy (MS) involves the analysis of peptides eluted from the MHC of antigen
presenting cells [40-42] or proteins in serum [43]. This area is reviewed more completely in the
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following reviews [44,45]. By using mass spectrometry, it has been demonstrated that as many
as 10,000 different peptide species are presented by individual class I MHC alleles [46]. The
technique, its strengths and limitations are extensively reviewed [47].
3.7. Protein microarrays
Protein microarrays involve the immunoscreening of protein arrays (approximately 9,000
full length proteins and functional domains) which may be purchased from companies such
as Invitrogen, Functional Genomics or Cambridge Protein Arrays. Antibodies in sera from
patients [33,48,49] can be detected using generic secondary antibodies (fluorescently conju‐
gated anti-human IgG) and visualised on microarray scanners.
4. Validation of the expression of tumour antigens in tumour cells
Once TAAs have been identified their expression in tumour cells needs to be confirmed.
There are a number of assays which can be used to validate the expression of antigens in
tumour cells. Many of the most frequently used rely on an available antibody which has
been validated [50,51]. Techniques frequently used include:-
4.1. Reverse Transcription (RT-PCR)/Real-time PCR
Total RNA is extracted from cells and used to make cDNA using reverse transcriptase. The
cDNA product is amplified by PCR and run on an agarose gel to identify the presence of the
transcribed gene in the cell [52]. This technique is sensitive and real-time PCR can provide
relative quantitation, however both techniques only indicate the presence/level of gene ex‐
pression and not protein translation, which can vary greatly between antigens.
4.2. Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-Linked Immunosorbent Assay (ELISA) is a straightforward procedure which can be
used to detect an antigen using an antibody [53]. The antigen is attached to the bottom of a 96-
well plate, or bound by a capture antibody on the bottom of a plate (in the case of a sandwich
ELISA). The protein of interest is then incubated with a chemically labelled detection anti‐
body. In most experiments the chemical label is an enzyme and a substrate is added which will
produce a colour change detectable by a microplate reader. The technique is sensitive and quan‐
titative when used in conjunction with appropriate protein concentration controls but is better
fitted to the analysis of protein in urine and blood, rather than in tissues.
4.3. Immunoblotting
Other systems which use antigen-antibody interactions are techniques such as Western blot.
Extracted proteins from tumours or cells are separated by 2-dimensional electrophoretic gels
and then blotted onto nitrocellulose membranes. The membranes are incubated with primary
and then secondary antibody. The secondary antibody is covalently labelled with an enzyme
which reacts with a substrate solution generating colour, which then can be measured [54].
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4.4. Immunoprecipitation
The protein of interest can be purified by incubating lysed cell extracts with its specific
antibody in solution. Once the antibody has bonded with the protein, the resulting complex
can be precipitated using agarose or G Sepharose beads which remove the required protein.
The complex can be separated using sodium dodecyl sulphate-polyacrylamide gel electro‐
phoresis [55]. The sample can then be used to determine how much protein is present relative
to other cells or other treatment conditions but denaturation is often required and details about
sub-cellular localisation are not possible.
4.5. Immunocytochemistry/histochemistry
The antigen of interest can be detected in cells (cytochemistry) or in tissues (histochemistry).
The cells or tissue sections are fixed onto slides using a fixative such as paraformaldehyde to
immobilise them. They are incubated with the primary antibody and then the secondary which
is labelled with a detection molecule. The technique is qualitative informing the user about the
sub-cellular localisation of the antigen in tissue and which cell types express it (Figure 1).
However quantitation is often lacking and like most methods this requires optimised reagents.
Figure 1. Demonstration of the sub-cellular localisation of the tumour antigen SSX2IP in K562 cells using immuno‐
fluoresence microscopy. Cells were air dried for 4-18hours onto glass microscope slides and stored at -20oC wrapped
in saranwrap. Cells were defrosted and stained with antigen specific primary and fluorescently labelled secondary an‐
tibodies. Using confocal microscopy we detected SSX2IP expression (observed as a green colour by virtue of anti-
SSX2IP-fluorescein isothiocyanate) was detectable on the surface of the K562 cells. Cell nuclei were stained blue using
4,6'-diamino-2-phenylindole (DAPI).
The advent of multiple tissue arrays from collaborators or commercial sources provides a
screening opportunity once the cancer(s) of interest for the antigen has been defined.
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4.6. Flow cytometry
This technique allows the analyses of cells with a variety of parameters such as extracellular
or intracellular markers, granularity, size and shape. Cancer cells are labelled with fluorescent
antibodies for the required antigen. The cells are passed in a stream and intersected with a
laser beam. The intensity of the fluorescence is measured and plotted in the form of dot plots
and histograms. This technique is sensitive and informative to allow specific cell types to be
“gated” by virtue of size, granularity and detectable protein expression. Machines can measure
up to 19 parameters in the most sophisticated machines allowing multiple proteins and cell
types to be analysed simultaneously [56]. However the technique requires validated antibodies
that have been shown to be appropriate for fluorescence activated cell sorting analysis and
enough tumour cells in suspension for analysis.
5. Identification of HLA-binding epitopes — in vitro assays
Immune responses in the body can ensure that any foreign matter is eliminated effectively.
Class I and II major histocompatability complexes (MHC) are present on the surface of
nucleated cells and present processed peptides from proteins inside the cell to T cells. T cells
can destroy infected cells if peptides in the context of “danger” are detected [57]. MHC in
humans is known as the human leukocyte antigen (HLA) system. MHC class I HLA molecules
are highly polymorphic and generally the best defence against infections.
5.1. MHC Peptide binding assay
Peptide antigens are stripped from the HLA class I molecules by mild acid treatment, cells are
then incubated with a fluorescent reference peptide together with different concentrations of
the peptide of interest. The efficiency with which the required peptide competes for binding
to the HLA class I molecules is examined by measuring the amount of HLA-bound reference
peptide with fluorescence activated cell sorting analysis [58].
5.2. T2 in vitro HLA-A2 binding assay
T2 in vitro HLA-A2 binding assay is more frequently used to determine the strength of peptide
binding to the most common HLA molecule in Caucasian populations. The HLA-A2 express‐
ing, TAP-1 deficient human T-cell line T2 is used as an assay of HLA-A2 peptide binding
efficiency. T2 cells are washed and resuspended in serum-free RPMI media and plated in 96-
well microtitre plates. Human β2-microglobulin and often nonamers (nine amino acids long
peptides) are added and the cells are incubated overnight at 37°C/5% CO2. The cells are washed
and probed with a HLA-A2-specific monoclonal antibody and appropriate secondary anti‐
body prior to flow cytometry. Only HLA-A2 molecules bound to peptide are stabilised and
detectable on the cell surface. Results are reported as a relative mean fluorescence index (MFI),
calculated as the MFI of peptide-pulsed T2 cells compared with the MFI of unpulsed T2 cells
[59]. Time course assays may be used to indicate how long the peptide remains on the HLA-
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A2, indicating how long T cells will have to interact with peptide bound HLA-A2 before the
complex falls apart.
6. In silico identification of epitopes
There are a number of databases which can be mined to find epitopes which have already been
shown to bind to HLA molecules. These have been used to identify established epitopes that
may be used in immunotherapy strategies.
6.1. The SYFPEITHI
The SYFPEITHI database allows the prediction of MHC class I and II binding ligands for
different  mammalian species.  When a  search is  carried out  using a  protein  sequence,  a
prediction  is  made  based  on  the  amino  acids  in  the  anchor  and auxiliary  anchor  posi‐
tions and other frequent amino acids which can bind to MHC molecules. A score is then
calculated which follows certain rules which are: a numerical value of 10 is given to ami‐
no acids that regularly arise in anchor positions, the value 8 is set for amino acids occur‐
ring  in  a  significant  number  of  ligands,  six  is  for  unusual  anchors  such  as  auxiliary
anchors and less frequent residues of the same set have a value of four. Preferred amino
acids have coefficients between 1–4 depending on the signal strength in pool sequencing
or the occurrence of individual sequences. Amino acids that are considered as having an
adverse  effect  on  binding  have  a  coefficient  of  –1  to  –3  [60].  SYFPEITHI  database  gets
updated regularly and has been used to identify various ligands; p28 peptide as an epit‐
ope  for  the  CT antigen  PLAC1 in  breast  cancer  [61],  p101-111  is  the  first  CTA-derived
peptide which induces CD4(+),  CD8(+),  and B-cell  responses in vitro  [62],  p43-57 epitope
stimulates T cells in HCA587-derived tumours [63] and PASD1(1) – PASD1(5) [51].
6.2. Bioinformatics and Molecular Analysis Section (BIMAS)
Bioinformatics and Molecular Analysis Section (BIMAS) develops computational processes to
analyse data generated from molecular biology and genetics research; and provides bioinfor‐
matics guidance, support and resources for the collection, management, and display of
biological sequence and genomic information for scientists involved in genomics and genetic
analysis [64]. Other online software which can be used to identify epitopes includes EpiJen,
Rankpep, nHLApred, NetCTL and Multipred [65].
7. Cell based assays — In vitro demonstration of T cell reactivity
There are a number of assays which can be used to determine if T cells are activated in response
to antigen.
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7.1. Carboxyfluorescein diacetate Succinimidyl Ester (CFSE)
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a cytoplasmic dye which is absorbed
by all cell types. Once the CFSE labelled cells divide, the dye is shared amongst the daughter
cells equally therefore the fluorescence is halved after each round of the cell cycle. This
difference in fluorescence can be measured. The more cells proliferate, the greater the decrease
in the fluorescent signal. The fluorescence peaks can be measured by flow cytometry [66]. CFSE
labelling is increasingly used to measure target tumour cell killing [67], superseding radiation
based assays, as well as T cell proliferation in response to tumour cells in vivo [68]. CFSE
labelling can also be performed in vivo where the dye is injected into the host animal’s spleen
or lymph nodes, however the labelling is not uniform and it is sometimes difficult to obtain
individual peaks once lymphocyte cell division has occurred [66].
7.2. Lymphocyte proliferation assays
Lymphocyte proliferation assays can be used to determine activation of T cells. Peripheral
blood mononuclear cells are isolated and cultured in microtitre plates. The specific antigen is
incubated with the cells, which causes the T cells to divide and grow. The MTT colorimetric
assay is based upon (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow
tetrazolium salt which gets cleaved by enzymes in the mitochondria to produce blue formazan.
Viable, dividing cells will create more formazan which can be quantified using a plate reader.
MTT assay is very convenient, however some considerations need to be assessed to avoid false
positives such as cell densities, correct culture medium, filtration of media to remove precip‐
itate, optimisation of MTT concentrations and incubation times [69].
7.3. [3H]-Thymidine incorporation assay
[3H]-Thymidine incorporation assay is  based on the use of  [3H]-thymidine a  radioactive
molecule  which  can  be  incorporated  into  DNA during  the  S-phase  of  cell  division.  As
new DNA is synthesised, occasional thymidine bases are replaced by [3H]-thymidine and
subsequently the incorporated radioactivity is measured, following washes to remove un‐
incorporated radioactivity, using a Scintillation Counter [70].  As [3H]-thymidine is radio‐
active  an  analogue  called  bromodeoxyuridine  (BrdU)  was  developed  to  replace  it  in
assays.  BrdU  integrates  into  DNA  strands  and  can  be  measured  using  immunohisto‐
chemistry  and  flow  cytometry  protocols  using  fluorescent  conjugates  and  can  be  ob‐
served over a longer duration. BrdU is also used to look at the number of cells in each
part of the cell cycle by flow cytometry [71]. However BrdU has been found to be more
toxic than [3H]-thymidine, possibly because it is structurally very different to the original
DNA nucleotides.  It  also adversely affects cell  division,  the pattern of cell  migration,  fi‐
nal position of migrating cells and the fate of labelled cells [72].
7.4. Peptide-MHC (pMHCs)
Peptide-MHC (pMHCs) based assays circumvent issues caused by measuring T cell prolifer‐
ation. T cell proliferation assays can provide information on whether an immune response has
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been generated but won’t determine which T cells, if they are indeed T cells, have been
activated. pMHCs, often referred to as tetramers, can be used to identify antigen specific T
cells. They are produced through the refolding of β2-microglobulin and heavy chains in MHC
molecules with the appropriate epitope of interest. The pMHC is then labelled with biotin
using BirA enzyme. A streptavidin molecule conjugated to a fluorescent detector binds to four
(tetramers) pMHCs or can used to create multimers (for example dimers, pentamers, dex‐
tramers) of these constructed MHC molecules courtesy of the biotin-avidin interaction [73]. T
cell populations are added to this mixture and T cells with the specific receptor for the epitope
of interest will bind and be measurable by flow cytometry [74]. Shen et al [74] have found that
cross-reactive T cells i.e. T cells which recognise two different antigens can be identified
providing an extra tool in vaccine development. In some cases antigen specific T cells may not
bind tetramers due to being undifferentiated and unable to accumulate T cell receptor (TCR)
molecules close to the antigen. Another reason could be low affinity between TCR and MHC
[75]. Other techniques based on the use of pMHCs include pMHC arrays [76] (Section 7.5),
NACS [77] and the combinatorial approach [78,79]. These techniques all provide high through‐
put analysis of multiple T cell populations with a variety of pros and cons to each technique
including issues with background, specificity/binding capacity of individual pMHC com‐
plexes, activated induced cell death of pMHC bound T cells, internalisation of pMHCs
following T cell binding [80], cost and labour intensity. Sequencing of TCRs (2-3 million every
2-3 days) by companies such as TRON gGmbH (Johannes Gutenberg University Mainz,
Germany) and Adaptive Biotechnologies (Seattle, USA) will provide a new way of analysing
T cell populations which will be informative with regards to which TCRs are present but not
necessarily whether they are present on mature, anergic, activated or functional T cells nor
which sub-group of T cells are harbouring them (helper T cells, cytotoxic T cells, Th17 cells or
indeed regulatory T cells (Tregs)). This technology allows the first opportunity to examine an
extremely large number of TCRs in a very short time and will revolutionise how we examine
T cell responses in patients in the future.
7.5. pMHC arrays
pMHC or tetramer arrays [76,81] (Figure 2) provides a strategy to determine which spe‐
cific  CD8+  T  cell  populations  are  present  in  the  peripheral  blood  of  patients.  Antigens
identified by the techniques described already can be used to help expand the pMHC ar‐
ray for future studies. In addition, the pMHC array provides a means to investigate epit‐
ope spreading and changes in T cell specificities with disease progression. The technique
benefits  from the  low number  of  purified CD8+  T  cells  required for  each array (0.5-2  x
106),  which can be purified from 20ml of  patient  peripheral  blood using StemCell  CD8+
negative isolation beads providing “untouched” T cells (Bonney, Guinn et al,  in prepara‐
tion).  The  purified  CD8+  T  cells  are  then  lipophyllically  dyed  with  DiD  (Molecular
Probes),  washed and incubated with the pMHC array. The pMHC array has a detection
limit of 0.02% matching the sensitivity we can reproducibly achieve with flow cytometry
when  analysing  patient  samples.  Where  sample  availability  permits,  pMHC  array  data
should  be  validated  by  flow cytometry  [82]  using  the  same pMHC tetramers  as  in  the
pMHC array. The pMHC array has the added advantage that it can be used for the ini‐
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tial  screening  of  a  relatively  small  number  of  CD8+  T  cells  against  a  large  number  of
pMHCs on the array, and a short-list of T cell populations which are shown to exist on
the pMHC array can then be quantitated by flow cytometry (limiting the amount of sam‐
ple  required  in  subsequent  studies).  The  pMHC  array  can  be  used  to  analyse  patient
samples at a number of disease time-points (presentation, post-treatment (surgery and/or
radiotherapy) and with disease progression) to examine how T cell responses to tumour
antigens change with treatment, to examine epitope spreading and to correlate changing
immune responses with clinical responses.
 
Figure 2. pMHC arrays for the simultaneous detection of T cell populations in patient peripheral blood. (A) Using a
QArray2 printer and HPLF 0.3mm solid tip pins (Genetix) we printed multiplexed AF532-conjugated pMHCs at a con‐
centration of 0.5mg/ml so that 1ng was placed in each spot (shown as coloured ovals). Each spot is 400uM wide with
a 700uM inter-spot distance. (B) At least six spots per pMHC are applied in each of two independent sites. Each hydro‐
gel slide can hold up to 1,000 spots of tetramer in total. (C) We applied 0.8-1.5 x 106 lipophillically-dyed CD8+ T cells/
slide (seen in red). pMHCs included a range of HLA restrictions and had already been shown to work in flow cytometry
studies,(i) pMHCs are spotted across the gel, (seen as green spots) (ii) even some HLA-A2 positive patients show no
reactivity with any pMHCs (iii) while others show the presence of multiple T cell populations which recognise tumour
antigens. Based on figure in [144].
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7.6. Intracellular cytokine staining assay
Intracellular  cytokine  staining  assay  detects  particular  cytokines  released  by  immune
cells which can provide a useful insight into the responding T cell populations. Such cy‐
tokines could include interferon-gamma (IFNγ), interleukin-2 (IL-2), IL-4 and tumour ne‐
crosis  factor-α.  Cells  are  plated  and  incubated  with  the  antigen  to  stimulate  cytokine
production.  To prevent  the cytokine from exiting the cell  a  transport  inhibitor  is  added
e.g.  brefeldin A.  The cells  are  then fixed in  paraformaldehyde and permeabilized to  al‐
low the anti-cytokine antibody to bind. The results are analysed by flow cytometry. The
use of intracellular cytokine staining assay to detect the cytokine IFNγ shows high repro‐
ducibility  and linearity  with little  background [83].  Duration of  culture prior  to  antigen
stimulation, as well as the cytokine accumulation period, are critical parameters of these
methods.  In both murine and cattle  models,  following 2-6 hours in culture,  T cells  pro‐
duced a mixture of  cytokines IFNγ, IL-2 and tumour necrosis factor-α,  however follow‐
ing 6-16 hours of culture only IFN-γ cytokine was found [84].
Using multiple peptides from distinct TAAs to stimulate immune cells may prove the most
effective for peptide vaccines. A cocktail of four multiple myeloma antigen peptides were used
to stimulate T lymphocytes from HLA-A2 positive people to induce IFNγ production, cell
proliferation and cytotoxicity against HLA-A2 positive multiple myeloma patients' cells [85].
Indeed long peptides may offer the advantage of allowing the immune system to choose the
epitope(s) it can best process and present from a peptide sequence and induce an effective
cytotoxic T cell response in the presence of longer CD4+ helper motifs [86]. Conversely
sometimes longer proteins can inhibit CD8+ T cells responses [87] but this may vary depending
on the constituents of individual protein sequences.
8. Cell based assays — In vivo assays
There are a number of approaches that can be taken when using mouse models to detect
T  cell  immune  responses.  Animals  can  be  used  in  transplantable  tumour  (xenografts)
models  or  genetically  engineered  tumour  models.  In  xenograft  models  human  tumour
cells are taken and injected into immunodeficient mice so that complex immune respons‐
es involving multiple cell types can be investigated. In contrast, in genetically engineered
models,  genes  known  to  cause  cancer  are  activated  or  tumour  suppressor  genes  are
“switched  off”  to  allow  their  effects  on  tumour  growth  to  be  examined.  In  addition
transgenic mice can be used to examine T cell responses to epitopes presented on MHC
molecules as described in this section.
8.1. Immunodeficient mice
Immunodeficient  mice  such  as  athymic  nude  mice,  severely  compromised immunodefi‐
cient  (SCID)  mice  and non-obese  diabetic  severe  combined immunodeficiency mice  will
accept  xenografts  of  human cells  [88].  Depending upon the number of  cells  injected,  or
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the size of the tumour transplanted, the tumour can develop over weeks to months and
the response to appropriate therapeutic  agents  studied in  vivo  [89].  Indeed such models
have been used to examine the effectiveness of various immunotherapeutic strategies in‐
cluding whole  cell  vaccines  [90],  dendritic  cell  (DC) vaccines  [91],  peptide vaccines  [92]
and DNA vaccines [67,87,93].
8.2. Genetically modified mice
Genetically modified mice may have genes which are overexpressed or deleted and the effects
of these genes on tumour development can be studied. Examples include p53 null and
heterogenous mice [94,95] demonstrated that these genes can act as oncogenes and lead to
tumour development. Possible therapies for these oncogenes/tumour suppressor genes are
tested for their response in an in vivo, full organism context [89] and examples include Ad-p53,
AAV-HGFK1 [96].
HLA-A2 transgenic mice have genes inserted into the DNA so they will express the HLA
molecules known in mice as H-2. In order to prevent the presentation of murine H-2-restricted
cytotoxic T lymphocyte (CTL) epitopes in HLA-A2 (AAD) transgenic mice, HLA-A2.1
transgenic/H-2 class I knockout mice (HHD mice) were created [97]. In HHD mice, the H-2
class I gene is knocked out, and a chimeric HLA-A2.1 monochain (HHD) is produced by linking
the C terminal of the human β2-microglobulin (unit of the class 1 MHC) covalently to the N-
terminus of the chimeric HLA-A2 heavy chain (which contain the α1&2 domains of HLA-A2.1
and the α3 domain of H-2Db) by means of a peptide bond. This guarantees the sole expression
of the HHD molecule on the cell surface, making sure that any identified CTL epitopes are
HLA-A2 restricted [98]. HHD mice allow epitopes which are presented on human HLA-A2 to
be examined for their ability to induce T cell responses in a variety of studies; for example
STEAP, a prostate tumour antigen has been shown to be targeted by anti-tumour T cells [99]
and DNA vaccines encoding Wilms tumour antigen 1 induce cytotoxic responses in mice [100]
using this model system.
9. Modes of immunotherapy
One of  the  biggest  debates  in  cancer  immunotherapy  remains  which  mode  will  be  the
most  effective.  The National  Cancer  Institute  have suggested that  immunotherapy stud‐
ies  should  focus  on  a  limited  number  of  antigenic  targets  to  maximise  the  chances  of
success [101]. However for some cancers effective immunotherapy targets have yet to be
discovered  (i.e.  ovarian  cancer,  adult  acute  lymphocytic  leukaemia)  and  better  targets
may yet be determined.
When T cells were found to be able to identify cancer cells [102] it was thought that T cell
therapies would be the most effective with the aim being to stimulate CD8+/CTL cells to kill
tumour cells. This can be achieved by a number of ways such as through the use of DCs [103],
peptide vaccines [85], DNA vaccines [104] and natural killer cells [105]. In recent years
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monoclonal antibodies (mAb) have become standard treatments for cancer. Ultimately if there
is an antibody and it recognises a surface antigen solely on cancer and non-essential cells then
this will likely be the most effective way to cause tumour destruction. mAbs are derived by
vaccinating an animal with the target antigen and testing to see if the B cells are producing
antibodies against it. Then the B cells are extracted from its spleen and infused with myeloma
cells to produce hybridomas. Hybridomas divide perpetually and produce the mAb to the
antigen in large amounts [106].
Rosenberg  et  al  [107]  showed  that  only  2.6%  of  immunotherapy  clinical  trials  had
worked and therefore an overhaul was needed in the practice of immunotherapy. Subse‐
quently  the  same group showed that  adoptive  T  cell  therapy  could  be  very  promising
with cell numbers being returned to the patient [108] and their status – activated but not
mature [109] and cell numbers being the main issues. It is also likely that the best strat‐
egy may include a combination of conventional and immunotherapy techniques [110] or
even  a  combination  of  immunotherapy  techniques  as  demonstrated  in  increasing  num‐
bers of mouse models [111] and clinical trials [112].
DCs are antigen presenting cells therefore they have received some attention for possible use
in cancer immunotherapy. DCs pulsed by peptide and injected into the skin showed a response
rate of 28%. This percentage increased to 35.7% when immature DCs are injected straight into
the tumour and even higher to 40% for advanced pancreatic cancer [113].
Tumour-infiltrating T cells (TIL) therapy has been used in stage IV melanoma patients. TILs
are obtained from the blood, lymph nodes or from a tumour tissue biopsy. TILs are isolated,
activated and expanded using IL-2 in vitro. The patient undergoes lympho-depleting chemo‐
therapy prior to the T cells being injected back in to the blood [114].
When a tumour antigen is  secreted into the circulation in high levels immune tolerance
can be induced in the thymus. CD8α−Sirpα+, a subset of DCs, are able to capture tumour
antigens  in  the  blood,  which  can  induce  tolerance  through  Tregs  or  negative  selection.
Tregs are cells which are part of the tolerance system which prevents autoimmunity [115,
116]. Simultaneous Treg depletions (using anti-CD25 antibodies for instance) may aid the
effectiveness of immunotherapy in some cancer types where Treg infiltration into the tu‐
mour is rife [117,118].
There are a number of reviews in this area of research which aim to look into effective
immunotherapy  strategies  for  the  future.  These  include  cellular  immunotherapy  [119],
whole call vaccines [120], multidrug resistance [121] and DCs [122]. Targeted therapeutic
strategies  along with  ever  improving designs  in  clinical  trials  pave  the  way for  further
success [123].
10. Clinical trials
Clinical trials are undertaken after a large amount of data has been obtained on the antigen of
interest in the lab. This data is required to ensure treatment safety and efficacy as far as is
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possible. It remains imperative in most countries that treatments have been tested on live
animals prior to first-in-man clinical trials and that favourable results are apparent in order
for treatments to be taken into clinical trials. People, often patients, are recruited as compen‐
sated or full volunteers. The drug is given to participants initially to show that it is safe and
then that it is effective. Dose escalation is also important so that an effective and safe dosage
in humans is used.
Clinical  trials  have  four  phases,  very  basically  as  follows:  І  –  evaluation  of  safety,  ІІ  –
safety  and  efficacy  (with  Phase  I/II  often  including  dose  escalation),  ІІІ  –  efficacy  in  a
large cohort  of  patients and ІV – post-approval studies.  Phase І  trials  look at  the safety
and the best dose of the drug to administer. Such trials often involve 13 patients or less,
and these patients  are  often have late  stage cancer  and are refractory to all  other  treat‐
ments  with  little  chance  of  recovery.  Phase  ІІ  trials  start  to  look  at  the  efficacy  of  the
medicine and often involve 20 patients with late stage disease. Phase І and ІІ trials have
to  be  completed successfully  in  order  for  testing to  proceed to  Phase  ІІІ.  Current  “best
practise” treatment is compared to the new drug being tested in phase ІІІ trials.  Only if
the  new drug offers  an improvement  over  best  practise  does  the  new medicine  have a
chance  of  becoming  the  standard  treatment.  At  this  time  the  drug  will  need  to  be  li‐
censed and approved by the authoritative body e.g. the US Food and Drug Administra‐
tion, and once licensed, phase ІV trials investigate the long term benefits and unexpected
side effects.  In some cases the drug may go through one of  the phases more than once
before moving forward and even then may get rejected [124].
It is very important that trials follow certain rules for the results to be considered legitimate.
Phase ІІІ trials need to be randomised i.e. a computer randomly puts people into one of two
groups. These can also be double-blind trials so that neither the patient nor the investigator
knows which treatment is being given, thus avoiding any bias. In some cases there may not
be any treatment to compare a new therapy against, in which case a placebo (inactive treat‐
ment) is given to one group [125]. In the UK the Medicines and Healthcare products Regulatory
Agency is responsible for the regulation of medicines and medical devices and equipment used
in healthcare, and the investigation of harmful incidents as well as overseeing the use of blood
and blood products [126].
Cohen et al [127] have created an online website called BreastCancerTrials.org which matches
patients to current trials taking place depending on the information they provide. This
provides a valuable source for cancer patients who may want initial guidance on which clinical
trials may be beneficial to them.
11. Assays to demonstrate efficacy of the response
Assays tend to reflect the immunotherapy strategy employed with the efficacy of antibody
therapies being measured by tumour destruction, ertumaxomab destroys tumour cells
expressing HER2/neu [128], bispecific antibodies represent a new class of anticancer thera‐
peutics [129] and antibody-targeted delivery of a vaccine can improve tumour cell killing [130].
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11.1. Enzyme-Linked Immunosorbent Spot (ELISPOT) assay
Enzyme-Linked  Immunosorbent  Spot  (ELISPOT)  assay  was  developed  by  Cecil  Czer‐
kinskdy in 1983 [131] and shows most similarity to the ELISA technique.  It  is  based on
the use of a 96 well plate with a polyvinyl-difluoride membrane to which antigen specif‐
ic  monoclonal  “capture”  antibodies  are  attached.  The  cells  are  grown  in  media  on  the
capture  antibody coated membrane usually  for  several  hours  to  overnight  and secreted
protein  (often  cytokines  such  as  IFNγ)  bind  to  the  capture  antibody.  A  second “detec‐
tion” antibody specific to the protein is used. This is  often conjugated to an enzyme al‐
lowing  a  chemical  reaction  to  occur.  Black  spots  form  on  the  membrane  wherever
protein  is  present  and these  can be  counted by an ELISPOT reader  [131].  ELISPOT as‐
says are one of the most sensitive ex vivo detection methods available with low detection
thresholds  in  peripheral  blood.  ELISPOT is  also  able  to  identify  patients  with  allergies
through the detection of drug-specific T cells in their blood [132].
11.2. Cultured ELISPOT
Cultured ELISPOT measures memory T cells. Cells are stimulated and plated on a 24-well
plate. After an incubation period half of the cell culture supernatant is removed and replaced
with Lymphocult (an IL-2 containing growth factor supplement). Fresh Lymphocult is added
again on day 7. On day 9, the cells are incubated overnight. On day 10, around 2.5x104 of the
originally plated cells are plated for a standard ELISPOT assay. Cultured ELISPOT assays
revealed the existence of longer-lasting T cell memory responses [133].
12. Conclusions
This chapter has focussed predominantly on the identification of epitopes within tumour
antigens and their validation as they enter clinical trials. Focus on clinical trials using antibody
therapies, DCs, natural killer cells, and adoptive therapy among many other options are the
focus of other excellent reviews in the field [134-136].
Cancer  immunotherapy is  a  vital  area  of  research that  continues  to  progress  at  a  pace.
Our  understanding  of  the  immune  response  and  its  potential  to  recognise  and  kill  tu‐
mour  cells  with  mans  guidance  offers  hope  to  the  patients  for  whom  few  other  treat‐
ment  options  exist.  Many  tumour  antigens  have  been  identified,  but  some cancers  still
lack antigen targets that are expressed in the majority of the cancer cells by the majority
of cancer patients.  New techniques to extend antigen discovery will  allow the improve‐
ment of immunotherapy strategies while the identification of new biomarkers will  assist
in  the  development  of  personalised  therapies.  Personalised  therapies  will  decrease  the
cost  (quantitative and qualitative)  of  treatment on patients  who are unlikely to respond
to  it,  allowing  patients  to  avoid  unpleasant  and  harmful  side  effects  while  maximising
patient quality of life.
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Target antigen Mode of
immunotherapy
Patient group Phase of
clinical
trial
Outcome Reference
CD22 Monoclonal antibody
conjugated to
calecheamicin
Refractory and
relapsed acute
lymphocytic
leukaemia
Phase 2 18% patients had complete
response, 39% had marrow
complete response, 39% had
resistant disease, and 4% died
within 4 weeks of starting
treatment
[137]
TG4010 targeting MUC1 &
IL-2
Poxvirus (modified
vaccinia virus Ankara)
in combination with
first-line
chemotherapy
Advanced non-
small-cell lung
cancer
Phase 2B 6-month progression-free
survival was 43·2% in the
TG4010 plus chemotherapy
group, and 35·1% in the
chemotherapy alone group
[138]
LY6K and TTK peptide vaccines in
combination with
CpG-7909
Metastatic
oesophageal
squamous cell
carcinoma
Phase 1 Vaccination with peptides in
combination with CpG-7909
increased and activated pDC
populations and NK cell
populations
[139]
CTLA-4 Monoclonal antibody
with glycoprotein
100 (gp100) peptide
vaccine
Previously treated
metastatic
melanoma
Phase 3 The median overall survival
was 10.0 months among
patients receiving ipilimumab
plus gp100, as compared with
6.4 months among patients
receiving gp100 alone
[140]
Prostate-specific antigen Poxviral vaccines Prostate cancer Phase 2 The primary end point was
progression-free survival
which was similar in the two
groups (treated, controls).
However, at 3 years post
study, treated patients had a
overall survival rate of 30%
compared to 17% of controls
[141]
CD20 Monoclonal antibody Relapsed or
refractory follicular
lymphoma
Phase 1/2 Treatment caused immediate
and profound B-cell depletion,
and 65% of patients reverted
to negative BCL2 status.
[142]
CA-125 Abagovomab, an
anti-idiotype
antibody
Ovarian Cancer Phase 1 Improved CA125-specific
cellular cytotoxicity might
indicate that longer
vaccination (nine injections)
would be preferred to short
(six injections)
[143]
Table 1. Examples of completed clinical trials showing the cancer antigen targets. Representation of the various
modes of immunotherapy employed to date, cancer patients treated and the outcome of the trials.
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